| 摘要 |
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, particularly to ophthalmology. Retinopathy stage IV-V diagnostic technique is ensured as follows. Birth body weight is measured with estimating application of erythrocytic mass transfusion, estimating type of infant feeding and delivery, 1-minute Apgar score, fraction of monocytes, birth body length, bilirubin level in blood serum. Herewith each considered indicator is specified with a diagnostic factor with informativity decrease. If erythrocytic mass transfusion is applied within 1-30 days of life, diagnostic factor is specified 0.41, otherwise diagnostic factor is (-)0.42. Breast feeding ensures diagnostic factor (-)0.43, while with artificial or mixed feeding diagnostic factor is 0.37. If 1-minute Apgar score is ëñ5 points, diagnostic factor is 0.33, while Apgar score >5 points shows diagnostic factor (-)0.45. If monocyte fraction within 1-7 days of life is >15%, set diagnostic factor is 0.42, while monocyte fraction within 1-7 days of life ëñ15% provides diagnostic factor (-)0.31. If natural delivery are applied, diagnostic factor is 0.31, and with operative delivery diagnostic factor is (-)0.37. If birth body weight is ëñ1400 g, diagnostic factor is 0.30, and if birth body weight is >1400 g, diagnostic factor is ^ (-)0.35. In birth body length ëñ40 cm diagnostic factor is 0.34, while in birth body length >40 cm, diagnostic factor is (-)0.29. Total bilirubin level within 1-7 days of life ëñ130 mkmol/l provides diagnostic factor 0.29, while total bilirubin level within 1-7 days of life >130 mkmol/l ensures diagnostic factor (-)0.33. The correction is ^ (-)0.056. It is followed with calculating total diagnostic factor considering the correction. If total diagnostic factor with informativity decreasing at certain analysis is at least 0.68, retinopathy stage IV-V in premature infants is considered to be diagnosed. If total diagnostic factor is 1.2 and less, retinopathy stage IV-V in premature infants is considered not to be observed. ^ EFFECT: method improves reliability and simplifies diagnostics of retinopathy stage IV-V in premature infants that reduces probability of blindness in infants caused by early change in therapeutic tactics. ^ 1 tbl, 3 ex |
